Medicare GLP-1 Bridge Denied—What Now?

By Weight Loss Provider Guide
Last verified: August 4, 2026 · Version 1.0

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We are not affiliated with Medicare, CMS, Humana, any Part D plan, or any drug manufacturer.

If you searched “Medicare GLP-1 Bridge denied—what now?”, start here: the message you saw may not be a final denial—and reject code 75 specifically is not final.

When a covered prescription reaches the Bridge and clears the program’s initial eligibility and claim edits, the first fill or a change to a different covered GLP-1 is expected to return reject code 75, “prior authorization required.” That rejection starts the prior-authorization handoff. It is not a final coverage decision. (CMS provider guidance; CMS reject-code tool)

A true Bridge denial is different. It is issued after your prescriber submits the prior-authorization form. And here is the part almost nobody gets right: the Medicare GLP-1 Bridge has no appeals process. CMS says so in writing. Your prescriber may resubmit when the original form contained incorrect information or when updated or additional information is available. CMS says the resulting PA decision is sent within 72 hours of submission; it does not promise unlimited retries or approval. (CMS provider guidance)

What changes the answer: a prescription for type 2 diabetes, moderate-to-severe obstructive sleep apnea, noncirrhotic MASH with moderate-to-advanced fibrosis, or reduction of major cardiovascular-event risk in an adult with established cardiovascular disease belongs in the Part D process rather than the Bridge. Those uses are coverable under Part D, but coverage is still subject to your plan’s formulary, utilization-management rules, coverage determination, and exception or appeal process. (CMS pharmacy guidance; official Bridge PA form; CMS Part D sponsor FAQ)

Now the part that made us build this page. We compared nine official Bridge source sets written for patients, prescribers, pharmacies, and Part D plans. They do not always present the same rule at the same level of detail. We found six paperwork seams that can make a correctable rejection look final or send a person into the wrong coverage process.

We will show you all six. First, let’s figure out what happened to you.

What kind of Medicare GLP-1 Bridge denial did I get?

Answer capsule: Start by separating a pharmacy claim edit, a completed Bridge PA denial, and a Part D coverage determination. The source, exact NCPDP code, and full message determine whether the next move belongs to the pharmacy, prescriber, Medicare, SSA, Part D plan, or a different eligible provider.

CMS’s current workflow, code tool, and Part D guidance support these different routes. (CMS provider guidance; CMS reject-code tool; CMS Part D sponsor FAQ)

First move: identify the source, exact code, and full message. Use the Bridge Denial Decoder on this page to match the message to the person who owns the fix. You do not need to enter your Medicare number, Social Security number, denial letter, or medical records.

→ Decode my Bridge rejection

What did we actually verify?

Answer capsule: We verified the Bridge workflow, eligibility criteria, covered products and NDCs, pharmacy codes, PA timing, help lines, appeal-versus-resubmission rule, Part D routing, and current commercial fallback prices against nine official or first-party source sets. We then converted CMS’s 40 reason rows across 30 distinct reject codes into nine patient-facing action groups.

On August 4, 2026, we read and cross-checked these official source sets:

• CMS Medicare GLP-1 Bridge — Information for Providers (page last modified 07/13/2026)
• CMS Medicare GLP-1 Bridge — Information for Pharmacies (page last modified 07/13/2026)
• CMS Medicare GLP-1 Bridge — Information for Part D Plans (page last modified 07/13/2026)
• CMS Medicare GLP-1 Bridge — Information for Medicare Beneficiaries
• The official Medicare GLP-1 Bridge Prior Authorization Request Form
• The CMS Prescriber Fact Sheet (CMS Product No. 12235, June 2026)
• The CMS Pharmacy NCPDP Reject Code Troubleshooting Reference Tool (June 2026)
• The CMS memorandum “Medicare GLP-1 Bridge: Expectations and Frequently Asked Questions for Part D Sponsors”
• The Medicare.gov weight-loss drugs coverage page and its eligibility tool

The provider, pharmacy, and Part D pages currently show a July 13, 2026 modification date. (CMS provider guidance; CMS pharmacy guidance; CMS Part D plan guidance)

Our original evidence block: the June CMS reject-code document contains 40 reason rows across 30 distinct NCPDP codes. We reorganized those rows into nine patient-facing action groups—the normal PA handoff, identity correction, eligibility or CMS/SSA status, product correction, quantity/timing correction, prescriber-identifier correction, replacement prescriber or pharmacy, retry/format correction, and long-term-care claim correction. The official document is organized for claims processing; the map below is organized around the question a patient needs answered: who can actually fix this? (CMS reject-code tool)

What we cannot tell you: whether you personally qualify, whether a specific Part D plan will cover a drug, whether a resubmission will be approved, or whether a pharmacy has stock. We cannot see your records, plan, claim, or prescribing purpose. What we can do is tell you which official rule applies and who controls the next step.

Medicare GLP-1 Bridge denied—what now? Was this the normal first step?

Answer capsule: A first Bridge claim is not automatically code 75 in every case. If the claim first clears identity, plan eligibility, previous Part D utilization, product, prescriber, quantity, timing, and formatting edits, code 75 is the expected “prior authorization required” response that starts the PA handoff. A different code means the pharmacy must resolve that issue before the PA can move forward. (CMS provider guidance; CMS reject-code tool)

Here is the sequence CMS actually built:

1. Your prescriber sends the prescription to your pharmacy.
2. The pharmacy runs the claim through the Bridge’s own billing route.
3. The central processor checks identity, eligible plan type, prior Part D GLP-1 utilization, product/NDC, prescriber, quantity, timing, and claim format.
4. If one of those checks fails, the pharmacy receives a specific reject code and resolution.
5. If those checks clear and prior authorization is required, the claim returns code 75.
6. The pharmacy transmits a PA request to your prescriber electronically or by fax, typically within 24 to 72 hours.
7. Your prescriber completes and submits the Bridge PA form.
8. CMS says the approval or denial is mailed to you and sent to the prescriber within 72 hours of submission. (CMS provider guidance)

That first rejection feels final because pharmacy rejections normally sound final. Here, code 75 means the computer is asking your prescriber to complete the next step.

That is not your fault. For years, “rejected at the pharmacy” has meant “your insurance said no.” A pharmacist writing in Pharmacy Times two weeks into the program described the same counter-level problem: patients were reading the PA-required rejection as a final coverage denial and leaving without the next step completed. (Pharmacy Times workflow report)

Even the official form says so. There must be a denied pharmacy claim submitted to Bridge BIN 028918 and PCN MEDDGLP1BR before the prescriber submits the PA. That is a Bridge claim prerequisite—not a requirement that your ordinary Part D plan deny the drug first. (official Bridge PA form; CMS provider guidance)

The one question that tells you where you stand

Ask yourself: Had my prescriber already completed and submitted the Medicare GLP-1 Bridge prior-authorization form when this happened?

• No → You may be at the expected PA handoff or an earlier claim edit. Get the exact code.
• Yes → You may have a true Bridge PA denial. Get the reason from the decision notice and give it to the prescriber.
• Not sure → Ask the office: “Did you receive and submit the Medicare GLP-1 Bridge prior authorization, and was it sent through the Bridge rather than my Part D plan?”

One more thing that trips people up

You do not need a Part D denial before a claim can be submitted to the Bridge. CMS says the prescriber may direct the pharmacist to send a potentially eligible weight-management claim directly to the Bridge. (CMS provider guidance)

Public comments posted during the first month of the program repeatedly described three points of friction: claims being sent to ordinary insurance first, unexplained delays between the pharmacy and prescriber, and uncertainty about whether mild sleep apnea should trigger a denial. Those comments are anecdotes about workflow confusion, not proof of eligibility or coverage. (Medicare Rights Center public comments)

Do this before you call anyone else: write down whether the message came from the pharmacy, the Bridge, or your Part D plan—and copy the exact code and full text.

→ Find the owner of my next step

Who actually denied me—the pharmacy, the Bridge, or my Part D plan?

Answer capsule: Three separate systems can produce a rejection connected to the Medicare GLP-1 Bridge, and they do not share one remedy. A pharmacy claim edit may belong to the pharmacy, prescriber, CMS, SSA, Part D plan, or a replacement provider; a Bridge PA denial may be resubmitted by the prescriber only when corrected, updated, or additional information is available; a Part D plan denial uses the plan’s coverage-determination and appeal process. (CMS reject-code tool; CMS provider guidance; CMS Part D sponsor FAQ)

Telling them apart is the single most useful thing you can do today.

It is a pharmacy claim rejection if…

• You found out at the counter, by phone, or in a pharmacy text
• There is an NCPDP code such as 65, 70, 75, 76, or E7
• The language is short and technical
• No completed-PA decision notice has arrived

Who fixes it: whoever the code identifies. Many are pharmacy corrections. Some require a prescriber, Medicare, Social Security, a Part D formulary-exception path, or a different eligible prescriber or pharmacy.

It is a Bridge prior-authorization denial if…

• Your prescriber already submitted the Bridge form
• A Bridge decision was mailed to you
• Your prescriber received the decision through ePA or fax
• The reason concerns Bridge eligibility, the requested product, initiation BMI, the prescribing purpose, or answers on the form

Who can resubmit it: the prescribing clinician, when the original information was incorrect or updated or additional information is available. The Bridge itself has no formal appeal. (CMS provider guidance)

It is a Part D denial if…

• The notice is a coverage determination from your Medicare drug plan
• It uses terms such as “coverage determination,” “redetermination,” “formulary exception,” or “right to appeal”
• It gives deadlines and instructions for challenging the decision

Who handles it: you, your representative, and your prescriber through the plan’s Part D process. A standard Part D benefit appeal is generally decided within seven days, and an expedited appeal within 72 hours when the health standard is met; follow the exact notice because deadlines and stages matter. (Medicare.gov Part D appeal guide)

A Part D denial does not always mean the claim went to the wrong place

If the prescription is solely for weight management and may satisfy Bridge rules, a Part D denial may signal misrouting. If the prescription is for a Part D-coverable use—such as type 2 diabetes, moderate-to-severe OSA, qualifying MASH, or cardiovascular-risk reduction—the Part D denial is a real decision in the correct system, and the answer is a coverage determination, exception, or appeal—not a Bridge rerun. (official Bridge PA form; CMS Part D sponsor FAQ)

Why the letter might say Humana even if you are not with Humana

CMS uses Humana, the administrator of Medicare’s LI NET program, as the Bridge’s central processor for prior authorization, claims adjudication, and pharmacy payment. Humana’s name can therefore appear on Bridge paperwork for someone whose Part D plan is not Humana. In that role, Humana is the federal demonstration’s processor—not necessarily your insurance plan. (CMS pharmacy guidance)

Practical takeaway: look at what the notice is deciding, not only the logo. A notice about a Medicare GLP-1 Bridge PA is a Bridge decision. A notice about your plan’s formulary or Part D coverage is a Part D decision.

What does my Medicare GLP-1 Bridge reject code mean?

Answer capsule: CMS’s June 2026 Pharmacy NCPDP Reject Code Troubleshooting Reference Tool contains 40 reason rows across 30 distinct codes. The full message matters because code 65 alone represents six different eligibility or status scenarios; the correct response ranges from a simple MBI correction to Part D follow-up, Medicare or SSA record resolution, or confirmed plan-type ineligibility. (CMS reject-code tool)

Do not accept “Medicare denied it.” Ask this instead:

“Can you read me the exact NCPDP reject code and the full message that came back?”

The number alone is not enough. We reorganized every official reason row around one question a patient actually cares about: who has to fix this?

Group 1—The normal PA handoff

Code 75

Code 75 means prior authorization is required. It is the expected next response when a covered claim has cleared the Bridge’s earlier eligibility and claim edits. The pharmacy initiates the PA request with the prescriber through ePA or fax; this code is not a final coverage denial. (CMS reject-code tool)

Who owns the next step: the prescriber, after the pharmacy confirms the PA request was transmitted.

Group 2—Your Medicare number or identity

Codes 7, CA, CB, 9, 52

The claim did not match the beneficiary information CMS expected. The MBI, first or last name, date of birth, or cardholder ID may be missing, invalid, old, or inconsistent with the CMS record. An MBI is the 11-character identifier on the red, white, and blue Medicare card. (CMS pharmacy guidance; CMS reject-code tool)

Common versions:

• The pharmacy used an old MBI or a former Health Insurance Claim Number
• The date of birth does not match the CMS record tied to the submitted MBI
• A required first-name, last-name, DOB, or cardholder field is blank or invalid

Who fixes it: the pharmacy first, using the current card and exact record information. If the pharmacy has the current MBI and the record still does not match, the patient may need Medicare’s help.

Why the pharmacy may ask for part of your Social Security number: Medicare.gov says a pharmacy may ask for your Medicare number or the last four digits of your Social Security number to help process the prescription or look up the MBI. Give sensitive information only through the pharmacy’s legitimate process or Medicare—not ordinary email or a public form. (CMS pharmacy guidance; Medicare.gov Bridge coverage page)

Group 3—Code 65, “Patient Is Not Covered”

One code covers six different messages.

Do not call the last three “database errors” unless the underlying status is actually wrong. The point is calmer and more accurate: the code is reporting a CMS/SSA status or record result, not making a medical judgment about you. (CMS reject-code tool)

On previous Part D use, CMS’s June sponsor memo says a beneficiary who received a GLP-1 through Part D in calendar year 2026 is not eligible for the Bridge in 2026. CMS’s current Part D page says it has not yet determined the relevant 2027 lookback period. Do not convert the 2026 rule into “ever.” (CMS Part D sponsor FAQ; CMS Part D plan guidance)

Group 4—Wrong product or NDC

Code 70

Code 70 means the exact National Drug Code submitted is not currently eligible for the Bridge. An NDC identifies a specific product, strength, and package, so two versions of the same brand can adjudicate differently. The official resolution is to rewrite for an eligible NDC when clinically appropriate. (CMS reject-code tool)

Who fixes it: the prescriber and pharmacy.

Group 5—Quantity, strength, days supply, timing, and duplicate claims

Codes 76, E7, 79, 15, 81, 82, 83, RK

The Bridge generally permits one 28- or 30-day supply per fill. It does not permit 60- or 90-day fills or partial transition fills. Code 76 can also mean the submitted tablet or capsule strength is not appropriate for the dose. E7 covers invalid quantity, NDC, ingredient amount, or a quantity that does not match the package size. (CMS pharmacy guidance; CMS reject-code tool)

Code 79 means “refilled too soon.” CMS says to resubmit when more than 75% of the prior days supply would have been used. For a 28-day supply, that means after day 21—normally day 22. For a 30-day supply, it means after 22.5 days—normally day 23. (CMS reject-code tool)

Codes 81, 82, 83, and RK describe a claim outside the filing period, a postdated claim, a duplicate claim, or an unsupported partial fill. The official tool lists no resolution for that particular invalid transaction; that does not mean the patient can never receive a future valid fill.

Who fixes it: usually the pharmacy; a corrected prescription may be needed.

Group 6—Prescriber identifier problems

Codes 25, 42, 56, 71, 619

The prescriber ID or Type 1 NPI may be missing, invalid, inactive, not found, or ineligible on the dated file. The pharmacy checks the identifier and resubmits according to the official resolution. CMS does not publish a guaranteed same-day timeline. (CMS reject-code tool)

Who fixes it: pharmacy and prescriber.

Group 7—A different prescriber or pharmacy may be required

Codes 543, 929, 930, A1, A2

These codes identify a foreign prescriber, a precluded or sanctioned prescriber, a deceased prescriber, or a precluded pharmacy. The official tool lists no correction under that same provider or pharmacy. In practical terms, a patient may need an eligible prescriber or pharmacy, depending on the code. (CMS reject-code tool)

Group 8—System or format problems

Codes 85, R8

Code 85 means the front-end switch was unavailable; the pharmacy resubmits later. R8 means the claim was not in the expected format; the pharmacy checks the format against NCPDP standards and resubmits. (CMS reject-code tool)

Group 9—Long-term-care claim fields

Codes 4X, U7

Long-term-care claims need a valid patient residence and pharmacy service type. The long-term-care pharmacy corrects those fields. (CMS reject-code tool)

Source note: NCPDP code descriptions are copyrighted material reproduced in CMS’s official troubleshooting tool. The nine action groups, plain-language routing, row count, and distinct-code count are Weight Loss Provider Guide’s assembled analysis.

Turn the code into an action. Copy the code, full message, drug/formulation, and who owns the next step into the pharmacy script below. That gives the counter something specific to solve instead of another round of “Medicare denied it.”

→ Use the pharmacy call script

Can I appeal a Medicare GLP-1 Bridge denial?

Answer capsule: No. CMS states that there is no appeals process under the Medicare GLP-1 Bridge. A prescriber may resubmit when the original form contained incorrect information or when updated or additional information is available. A separate Part D denial still carries the normal Part D coverage-determination, exception, and appeal rights. (CMS provider guidance; CMS Part D sponsor FAQ)

We want to be very direct with you, because you may have read otherwise.

CMS’s current provider page says:

“There is no appeals process under Medicare GLP-1 Bridge.” (CMS provider guidance)

The correction we have to make

Some denial guides blur a Bridge denial into the ordinary Part D appeal ladder. That is not the process CMS describes: the Bridge itself has no appeal, while a separate Part D coverage decision retains the Part D appeal process. (CMS provider guidance; CMS Part D sponsor FAQ)

There are no Bridge appeal levels. The Part D appeal system remains intact, but it applies to a Part D coverage decision—not to a denial issued by the Bridge.

We are not saying that to score a point. We are saying it because filing the wrong process can burn time while the correctable problem sits untouched.

Here is our honest admission—and why it is better news than it sounds

The Bridge does not give you a formal appeal right. That is a real limitation and we are not going to soften it. There is no Bridge-level independent review path, and a service cannot manufacture one for you.

But a correctable denial is not necessarily the end. CMS expressly permits the prescriber to resubmit if information was wrong or if updated or additional information is available. The current guidance does not state a numeric retry limit, but that is not the same as promising “unlimited resubmission.” Repeating the same unchanged form is not the remedy CMS describes. (CMS provider guidance)

CMS says a PA approval or denial is communicated within 72 hours of submission. That is the decision window—not a guarantee that every correction will be approved or that every office will submit immediately. (CMS provider guidance)

If your situation genuinely needs formal appeal rights because the drug is being requested through Part D for a Part D-coverable indication, that path remains open. See the Part D section below or the site’s general GLP-1 prior-authorization guide.

When resubmission makes sense

• The form used the wrong BMI date
• A response was incorrect or incomplete
• A qualifying diagnosis or required detail was omitted
• New or updated documentation is available
• The requested product or formulation was wrong
• The prescribing purpose was routed to the wrong coverage system

We cannot tell you a resubmission will be approved. Nobody who cannot see the record can.

One caution about the form

The prescriber signs an attestation that the information is true, accurate, and complete, and CMS says the program may independently verify PA information against Medicare data. That is why the answer to a denial is never “just check a different box.” It is: “Let’s make the form match the record and the actual prescribing purpose.” (official Bridge PA form; CMS prescriber fact sheet)

Where can the Medicare GLP-1 Bridge paperwork send me down the wrong path?

Answer capsule: The official materials are consistent on the core rules, but they present several rules at different levels of detail. We found six current seams: the required Bridge claim versus an unnecessary Part D denial, broad “fatty liver disease” wording versus the exact MASH criterion, shorthand hypertension wording versus the form’s medication threshold, cumulative BMI tiers displayed as separate bands, initiation BMI versus current BMI, and present-tense Part D language versus the 2026 utilization lookback. (CMS provider guidance; official Bridge PA form; Medicare.gov Bridge coverage page; CMS Part D plan guidance)

This is the section we built this page for. The table and routing analysis below are our own cross-document comparison of these six seams.

We are not accusing anyone of anything. A new federal demonstration spread across beneficiary pages, provider pages, pharmacy tools, a PA form, and a sponsor memo is going to have seams. But the seams are landing on real people, and you deserve to see them.

Seam 1—A denied Bridge claim is required; a Part D denial is not

The PA form says there must be a denied pharmacy claim submitted to Bridge BIN 028918 and PCN MEDDGLP1BR before the prescriber submits the PA. The provider FAQ separately says a Part D denial is not required. Both are true because they refer to different claims. (official Bridge PA form; CMS provider guidance)

Why this matters: an office can waste days chasing a Part D denial that the Bridge never asked for, while another office may incorrectly think the code-75 Bridge rejection means the patient failed.

Seam 2—“Fatty liver disease” is broader than the actual Part D-routing criterion

Medicare.gov’s beneficiary tool asks whether the person has “fatty liver disease.” The official PA form asks the exact question: noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver scarring (fibrosis). The broad patient wording is not a safe substitute for the form’s exact diagnosis. (Medicare.gov Bridge coverage page; official Bridge PA form)

Why this matters: a chart entry for steatosis or a broad fatty-liver diagnosis does not, by itself, answer the form’s MASH-and-fibrosis question. The prescriber should use the actual diagnosis and record—not a patient-page shorthand.

Seam 3—“Uncontrolled high blood pressure” has a definition the patient tool does not show

Medicare.gov names “uncontrolled high blood pressure.” The prescriber criteria define it as systolic pressure above 140 mm Hg or diastolic pressure above 90 mm Hg despite concurrent treatment with two antihypertensive medications. (CMS provider guidance)

Why this matters: a person can reasonably read “uncontrolled high blood pressure” and assume any high reading qualifies. The prescriber must answer the narrower CMS definition.

Seam 4—The BMI thresholds are cumulative even though the form uses separate BMI bands

The criteria are written as BMI at least 30 with one of three conditions or BMI at least 27 with one of four other conditions. Someone with BMI 32 is also at least 27. Medicare.gov’s eligibility tool confirms that the 30–34.9 branch accepts all seven conditions, while the 27–29.9 branch accepts the four lower-threshold conditions. The PA form then asks all of the condition questions after the prescriber selects one BMI band. (CMS provider guidance; Medicare.gov Bridge coverage page; official Bridge PA form)

Why this matters: a prescriber should not exclude prediabetes, previous MI, previous stroke, or symptomatic PAD merely because the selected BMI band is 30–34.9.

A public commenter described the exact confusion before the cumulative reading was made explicit: Medicare.gov appeared to allow prediabetes at BMI 30 or higher, while the prescriber criteria looked as though prediabetes belonged only to the lower tier. The current eligibility tool resolves that conflict by returning all seven conditions for BMI 30–34.9. The comment is evidence of wording friction, not authority for the rule. (Medicare Rights Center public comments; Medicare.gov Bridge coverage page)

Seam 5—The form wants initiation BMI, not automatically today’s BMI

The PA form says to select the BMI at the time GLP-1 therapy was initiated and specifically instructs the prescriber to use the initial BMI if treatment lowered it. CMS also applies the clinical criteria at initiation for people who began therapy before the Bridge. (official Bridge PA form)

Why this matters: medical offices normally use current vitals. That habit is reasonable almost everywhere else and wrong for this question.

If your BMI fell after treatment and the denial cites BMI, check this first. Records that may help the office identify initiation BMI include visit notes, recorded height and weight, prescription history, and old PA documentation. Those records do not guarantee approval; they help the prescriber answer the correct date-specific question.

Seam 6—“Already get” is not the full 2026 lookback rule

Medicare.gov asks whether you have taken a GLP-1 covered by your Medicare drug coverage. The sponsor memo says a beneficiary who received a GLP-1 through Part D in calendar year 2026 is not eligible for the Bridge in 2026. CMS says it has not yet determined the lookback period it will use in 2027. (Medicare.gov Bridge coverage page; CMS Part D sponsor FAQ; CMS Part D plan guidance)

Why this matters: a Part D-paid fill earlier in 2026 can count even if you are no longer taking that drug. A fill from a prior year should not automatically be described as disqualifying under the published 2026 rule.

One sleep-apnea clarification that no longer belongs in the “gap” list

The current Medicare.gov page, provider page, pharmacy page, sponsor memo, prescriber fact sheet, and PA form use the moderate-to-severe threshold. Mild OSA is not what Question 2 asks. If a Bridge PA was denied solely because the record shows mild OSA, the prescriber should compare the denial reason with the current form and decide whether corrected information supports resubmission. (official Bridge PA form; Medicare.gov Bridge coverage page)

Public comments show why this distinction matters in practice. One person reported a denial that she believed was based on mild sleep apnea and asked how to appeal; another person with a reported BMI above 35 said she was told that slight OSA made her ineligible. These reports do not establish what the processor decided or whether either person qualified. They show the exact paperwork question the current form can resolve: Question 2 asks about moderate-to-severe OSA, not mild OSA. (Medicare Rights Center public comments; official Bridge PA form)

What all six seams have in common

They all punish shorthand. “Denied,” “fatty liver,” “high blood pressure,” “BMI tier,” “already covered,” and even “insurance denial” are not specific enough to route the case.

That is not you being careless. That is a paperwork system that requires the exact source, code, date, diagnosis, and prescribing purpose.

Take the exact issue to the prescriber—not a general complaint. Use the handoff checklist below to name the seam, the current CMS rule, and the field that needs review.

→ Open the prescriber resubmission checklist

I was denied because of diabetes, sleep apnea, MASH, or heart-risk treatment. Is that final?

Answer capsule: A Bridge denial does not decide a separate Part D coverage request. If the prescription is for type 2 diabetes, moderate-to-severe OSA, noncirrhotic MASH with moderate-to-advanced fibrosis, or reduction of major cardiovascular-event risk in an adult with established cardiovascular disease, CMS routes the request to Part D. Part D coverage is not automatic, but its coverage-determination, exception, and appeal rights remain intact. (official Bridge PA form; CMS Part D sponsor FAQ)

Read that again, because it is the most important paragraph on this page.

A Bridge denial closed one particular door. It did not decide whether your Part D plan must cover the prescription after applying its own formulary and utilization-management rules.

Why these uses are carved out

The basic Part D benefit generally excludes agents when used for weight loss. The Bridge is a temporary demonstration operating outside Part D for eligible weight-management use. A GLP-1 prescribed for a currently Part D-coverable indication belongs in the Part D lane instead. (CMS Part D benefit manual; CMS Part D sponsor FAQ)

The PA form identifies four Part D-routing situations:

• Moderate-to-severe obstructive sleep apnea
• Noncirrhotic MASH with moderate-to-advanced fibrosis
• Type 2 diabetes
• A drug prescribed to reduce major adverse cardiovascular-event risk in an adult with established cardiovascular disease (official Bridge PA form)

A diagnosis on the chart and the purpose of this prescription both matter. CMS says a person with previous MI, stroke, or symptomatic PAD can still satisfy a Bridge clinical threshold when the drug is prescribed for weight management. But if the drug is being prescribed to reduce MACE risk, the request belongs in Part D. (CMS Part D plan guidance)

What you gain by being routed to Part D

The Bridge has no appeal. Part D does.

CMS says the Bridge does not modify Part D coverage-determination requirements or beneficiary appeal rights, including exception requests. That means a plan denial can proceed through redetermination and independent review under the Part D rules. Follow the notice you received; standard and expedited response times differ. (CMS Part D sponsor FAQ; Medicare.gov Part D appeal guide)

And CMS is watching the plans

CMS told Part D sponsors they must continue handling GLP-1 requests for Part D-coverable indications and must not deny or limit access in a way that improperly pushes beneficiaries into the Bridge. CMS said it would monitor utilization-management and formulary-exception patterns for inappropriate shifting. (CMS Part D sponsor FAQ)

That does not guarantee your plan will approve the drug. It means the plan cannot treat the Bridge as a substitute for its Part D obligations.

The gap that still lands hard

We are not going to pretend everyone lands somewhere good.

A person can have a diagnosis that routes the request away from the Bridge and still face a Part D formulary denial, utilization-management requirement, or unaffordable cost sharing. CMS also says Bridge eligibility does not change merely because the $50 copay would be cheaper than the Part D cost. (CMS Part D sponsor FAQ)

If that is you, the real options are:

• Ask the plan for a coverage determination or formulary exception
• Appeal an adverse Part D decision using the instructions on the notice
• Check whether Extra Help or a Medicare Savings Program may reduce costs for Part D-covered drugs
• Get free case-specific help from SHIP or the Medicare Rights Center

Extra Help does not reduce the Bridge’s separate $50 copay, but it can reduce qualifying Part D costs. (CMS Part D sponsor FAQ; SHIP)

One thing CMS encouraged Part D plans to do

CMS strongly encouraged—but did not require—Part D sponsors to return this free-text routing message when a weight-management claim may belong in the Bridge:

FOR OBESITY: BIN 028918 PCN MEDDGLP1BR

If that message was absent, it does not invalidate the denial. It does mean you can ask the pharmacy whether the prescription should instead be submitted to the Bridge. (CMS Part D sponsor FAQ)

Was it the drug, the pen, the NDC, or the amount?

Answer capsule: The current Bridge list includes all currently listed Foundayo tablet strengths, Wegovy injection and tablets—including Wegovy HD—and Zepbound KwikPen. Zepbound single-dose vials and single-dose pens are excluded. An ineligible NDC returns code 70; an invalid days supply, strength, ingredient amount, or package quantity can return code 76 or E7. (CMS pharmacy guidance; CMS reject-code tool)

If your rejection was code 70, 76, or E7, this section is your answer.

What is currently covered

CMS added Foundayo on April 6, 2026 after FDA approval and clarified that only the KwikPen formulation of Zepbound is included. CMS says the product and NDC list may be updated during the program. (CMS pharmacy guidance)

Current covered NDCs

Last checked: August 4, 2026. This table converts the current CMS list into a code-70 verification block the patient, prescriber, and pharmacy can check together.

CMS says this list can change during the Bridge, so the page should never present these codes without the visible verification date. (CMS pharmacy guidance)

What to ask after code 70: “Which exact NDC was submitted, and is it one of the current Bridge NDCs?” If the product or formulation is wrong, the prescriber decides whether a covered alternative is clinically appropriate.

Two costs and restrictions that can surprise you

Pen needles are not covered. CMS says Zepbound KwikPen needles should not be billed to the Bridge or the patient’s Part D plan; the patient purchases them separately. (CMS pharmacy guidance)

Coupons and discount programs cannot be applied to a Bridge claim. The eligible beneficiary copay remains $50. (CMS pharmacy guidance)

One rule that can cost you real money

The central processor accepts electronic pharmacy claims only. It does not accept paper claims or direct member reimbursement. If you pay full cash price while the claim is unresolved, the Bridge does not provide a later receipt-submission path to reimburse you. (CMS pharmacy guidance)

If you are tempted to pay cash just to end the wait, read that twice first.

The list can change

CMS explicitly says the covered products and NDCs may be updated. Keep the visible Last verified date beside this table and recheck the CMS list monthly while the program is new. (CMS pharmacy guidance)

What exactly should I ask my pharmacy?

Answer capsule: Ask for the complete NCPDP reject code and message, then confirm the claim was submitted to Bridge BIN 028918 and PCN MEDDGLP1BR with the current MBI. Pharmacies do not need to enroll or opt in, and CMS provides a pharmacy help desk at 844-673-0910 for claim-submission questions and submitted-claim status. (official Bridge PA form; CMS pharmacy guidance)

Copy this. Say it word for word if that is easier.

“Could you tell me the complete NCPDP reject code and the full message that came back? Can you confirm this was sent to the Medicare GLP-1 Bridge using BIN 028918 and PCN MEDDGLP1BR with my current MBI—not through my regular Part D billing route?”

BIN and PCN are routing numbers that tell the pharmacy system which payer to bill. If a weight-management claim goes to the Part D route instead, the plan may reject it because it never reached the Bridge.

The checklist for your pharmacist

• Current MBI from the current Medicare card
• First name, last name, and date of birth exactly as CMS has them
• BIN 028918 / PCN MEDDGLP1BR
• Current covered product and NDC
• Correct strength, package quantity, and ingredient amount
• One 28- or 30-day supply—not 60 or 90
• Valid prescriber Type 1 NPI
• Exact response code and full message
• Whether code 75 generated the PA request to the prescriber

“We are not part of that program”

A pharmacy does not have to opt in to the Bridge. The useful follow-up is not an argument about enrollment. It is: “Can your system submit this claim to the Bridge BIN and PCN, or can your pharmacy help desk assist?” (CMS pharmacy guidance)

If you are still stuck

1. Ask for the pharmacist or pharmacy manager.
2. Give them the BIN and PCN in writing.
3. Ask for the exact code and complete message.
4. Ask the pharmacy to call the Medicare GLP-1 Bridge Pharmacy Help Desk: 844-673-0910.
5. Call 1-800-MEDICARE for your eligibility or PA status when the issue belongs to Medicare.
6. Use a different pharmacy only when the code or unresolved pharmacy workflow supports that move.

The first month’s public comments included a beneficiary whose pharmacy reportedly refused to submit a BMI-35.7 case without another condition. The current CMS criteria say BMI at least 35 meets the clinical BMI threshold without one of the listed additional conditions. That anecdote does not prove what happened in that claim, but it shows why asking for the actual code and rule matters. (Medicare Rights Center public comments; CMS pharmacy guidance)

Bring one specific problem to the counter. “Please fix code E7” gets action. “Medicare denied me” gets another loop.

→ Copy the seven-step action checklist

What does my doctor need to fix before resubmitting?

Answer capsule: Only a prescribing clinician can submit the Bridge PA. Before resubmitting, the office should verify that the required Bridge claim occurred, use the correct coverage lane and product, select BMI at GLP-1 initiation, apply the cumulative BMI thresholds, answer every clinical question accurately, and include corrected, updated, or additional information that addresses the denial. (official Bridge PA form; CMS provider guidance)

You cannot file the Bridge PA yourself. That is printed on the form.

With no Bridge appeal available, the prescriber is the person who can submit a corrected Bridge PA. A pharmacy, Medicare, SSA, or Part D plan may still own a different part of the problem, depending on the code.

The seven-point resubmission check

1. Did the required claim reach the Bridge?
The form requires a denied claim through Bridge BIN 028918 and PCN MEDDGLP1BR before PA submission. A Part D denial does not satisfy that Bridge prerequisite and is not required. (official Bridge PA form; CMS provider guidance)

2. Is the correct coverage lane being used?
Question 1 routes type 2 diabetes, moderate-to-severe OSA, noncirrhotic MASH with moderate-to-advanced fibrosis, and MACE-risk-reduction prescribing to Part D. Weight-management use without one of those Part D-routing situations continues through the Bridge. (official Bridge PA form)

3. Is the BMI from the correct date?
Use BMI at GLP-1 therapy initiation. If treatment lowered it, the form says to select the initial BMI. (official Bridge PA form)

4. Are the cumulative thresholds being applied correctly?

The ≥30 and ≥27 thresholds are cumulative. Medicare.gov’s 30–34.9 branch returns all seven conditions. (CMS provider guidance; Medicare.gov Bridge coverage page)

5. Are all required questions completed accurately?
The form asks about Part D routing, OSA severity, exact MASH status, type 2 diabetes, initiation BMI, prediabetes, previous MI, previous stroke, symptomatic PAD, HFpEF, CMS-defined uncontrolled hypertension, and CKD. Missing or inconsistent information can prevent a clean decision; do not call every blank automatically “fatal,” because the resulting action depends on the actual notice. (official Bridge PA form)

6. Is the cardiovascular prescribing purpose clear?
The Bridge form does not require the prescriber to attest that the patient has no established cardiovascular disease. But if the drug is being prescribed to reduce MACE risk, the prescription belongs in Part D—even if weight management is also a goal. (CMS Part D plan guidance)

7. Is the administrative information complete?
Patient name, current MBI, DOB, address; prescriber contact, NPI, Tax ID, fax and phone; requested drug; signature and date.

How it gets submitted

The current CMS form accepts electronic PA through CoverMyMeds or fax at 1-800-530-2404. Always use the number on the live form because operational details can change. (official Bridge PA form)

CMS recommends adding an E66-family obesity diagnosis code and the annotation “SEND TO BRIDGE FOR WEIGHT MANAGEMENT” to help route the prescription. The current provider FAQ says the diagnosis code and annotation are recommended—not required for Bridge processing. (CMS provider guidance)

For a complete appointment-prep list, use the site’s Medicare GLP-1 Bridge paperwork guide.

The prescriber help line

855-273-0102, Monday through Friday, 8 a.m. to 7 p.m. Eastern, for prescriber PA questions and status. (CMS provider guidance)

What if my current prescriber will not evaluate or submit the Bridge PA?

Your current prescriber is still the best first choice when that office has your initiation BMI, diagnoses, and medication history. If the office will not handle the Bridge or you do not have a prescriber, Sesame currently states that its Medicare-focused weight-loss membership starts at $59 per month, that a provider confirms Medicare coverage and submits the PA when medication is appropriate, and that the separate medication copay is $50 per month if the patient qualifies for the Bridge. That is a paid clinician-access route, not an approval guarantee, and it is unnecessary if your current prescriber will do the work. (Sesame Medicare program)

This link may be an affiliate link. We may earn a commission at no additional cost to you. The commercial relationship does not change the Bridge rules or the recommendation to use your existing prescriber first.

If the missing piece is a willing prescriber—not a different medication: See Sesame’s current Medicare visit details.

Make the ask easy. Send the office the denial reason, initiation-BMI record, correct product, exact coverage lane, and the CMS source that addresses the disputed field. Do not send your Medicare number through an ordinary unsecured email.

→ Print the prescriber handoff checklist

How long should this take?

Answer capsule: After the pharmacy determines that a Bridge PA is required, CMS says the pharmacy typically transmits the request to the prescriber within 24 to 72 hours. Once a completed PA is submitted, the approval or denial is mailed to the patient and sent to the prescriber within 72 hours. Pharmacy corrections, office response time, stock, and Part D processes can add time outside those windows. (CMS provider guidance)

If more than 72 hours pass and the prescriber never received the request, CMS says the prescriber can download the fax form and submit it directly rather than waiting indefinitely for the handoff. (CMS provider guidance)

It can move quickly—but one fast case is not a promise

A public commenter reported an endocrinology visit on June 30, form submission July 1, and a $50-ready pharmacy text July 2. That is useful proof that the workflow can complete quickly. It is one person’s anecdote, not a typical-result claim or a guarantee. (Medicare Rights Center public comments)

Good news once you are approved

Current Bridge PA approvals are valid through December 31, 2027, including refills and dose changes, unless the patient switches from one covered GLP-1 drug to a different covered GLP-1. A switch requires a new PA. (CMS pharmacy guidance)

You should not need a new PA every month under the current rule. You may still encounter refill-timing, quantity, stock, or pharmacy-claim issues.

Who do I call when everyone points at someone else?

Answer capsule: Beneficiaries should call 1-800-MEDICARE for Bridge eligibility questions and PA status. Prescribers have a separate Bridge line at 855-273-0102. Pharmacies have a claim help desk at 844-673-0910. SHIP and the Medicare Rights Center provide free Medicare counseling and Part D appeal help. (CMS pharmacy guidance; Medicare.gov Bridge coverage page; Medicare Rights Center public comments)

SHIP provides free, one-on-one Medicare counseling; its national locator number is 1-877-839-2675. (SHIP)

Where Bridge complaints go: CMS told Part D sponsors to direct Bridge-specific beneficiary questions to 1-800-MEDICARE. Your plan remains responsible for its own Part D coverage decisions. (CMS Part D sponsor FAQ)

What to say when you call Medicare

“I am calling about the Medicare GLP-1 Bridge demonstration, not a normal Part D weight-management claim. Can you tell me whether a Bridge prior authorization was received, its current status, and whether my plan type is eligible?”

What the prescriber can ask

“The patient received a Medicare GLP-1 Bridge denial. We need the denial reason and need to confirm whether corrected, updated, or additional information can be resubmitted.”

Please do not email your Medicare number

CMS’s technical mailbox says not to include personally identifiable or protected health information in ordinary inquiries. For a personal status or eligibility question, call the proper support line instead. (CMS provider guidance)

What if the denial means I really do not qualify?

Answer capsule: If the denial reflects confirmed ineligibility rather than a claim or documentation problem, sending the same unchanged Bridge request will not create eligibility. The remaining routes are Part D for a coverable indication, a manufacturer or pharmacy self-pay route for an FDA-approved brand, or a separate telehealth cash-pay program. None is the Bridge. Cash-pay routes cost more than the Bridge’s $50 copay; Part D cost varies by plan, formulary, benefit phase, and subsidy eligibility. (Medicare.gov Bridge coverage page; CMS Part D sponsor FAQ)

Before you read further, one honest instruction:

If your prescriber still has a legitimate Bridge correction or resubmission path, stop here and use it. Fifty dollars per monthly supply beats every cash-pay option below. We would rather you close this page and call the office than click an affiliate link you do not need.

Still here? Then let’s be practical.

First, name the reason

Do not change Medicare drug coverage based on one article. Enrollment decisions can affect premiums, formularies, pharmacies, employer or union coverage, TRICARE coordination, and late-enrollment penalties. Use SHIP or 1-800-MEDICARE before changing plans. (SHIP)

Route 1—Your Part D plan

This is the first route when the drug is prescribed for a Part D-coverable indication. Ask for the plan’s coverage determination or formulary exception. If the plan denies it, follow the appeal notice. The Bridge does not weaken those rights. (CMS Part D sponsor FAQ; Medicare.gov Part D appeal guide)

Free help exists: SHIP and the Medicare Rights Center do not sell a telehealth program.

Route 2—Manufacturer and direct-pharmacy self-pay pricing

These are separate cash transactions, not Medicare or Bridge claims. Terms, doses, and eligibility can change, so verify them on the manufacturer’s live page before paying.

These are manufacturer-published cash prices, not our estimates and not guarantees of eligibility. The Zepbound figures are for the single-patient-use KwikPen—the same formulation category the Bridge covers, but purchased outside the Bridge under separate self-pay terms. (official Wegovy pricing; official Foundayo pricing; official Zepbound pricing)

Medicare.gov also points people who do not qualify toward manufacturer assistance, state pharmaceutical-assistance programs, mail-order price checks, and TrumpRx price comparison. It says purchases made with discount cards instead of the Medicare plan do not count toward the Part D deductible or out-of-pocket maximum. (Medicare.gov Bridge coverage page)

Route 3—Telehealth for an FDA-approved brand

This is the first place a commercial option genuinely fits: someone who has finished the Bridge troubleshooting, does not have a workable Part D route, and has consciously chosen an FDA-approved cash-pay medication.

Provider-stated versus verified

Ro’s and Sesame’s statements are provider-stated commercial facts, not CMS guarantees. (Ro official pricing; Sesame Medicare program)

If you have confirmed that neither a Bridge correction nor a workable Part D route applies and you want a familiar telehealth program with FDA-approved cash options, Ro is the first commercial cash-pay fallback we would check. Its current membership is $39 for the first month, then $149 monthly or as low as $74/month on an annual prepaid plan, and medication is separate. (Ro official pricing)

Be clear about what this is and is not. Ro is not the Medicare GLP-1 Bridge. A Ro membership does not turn a cash purchase into Medicare coverage. We are not claiming Ro files Bridge resubmissions.

Sesame serves a different blockage: the reader still needs a clinician willing to evaluate the Bridge and submit the PA. Sesame currently states that membership starts at $59/month and is billed separately from the $50 Bridge medication copay for eligible patients. It is not a promise that a particular clinician, state, or patient will qualify. (Sesame Medicare program)

Some links in this section may be affiliate links. We may earn a commission at no additional cost to you. Affiliate relationships did not affect the CMS rules, code map, Part D routing, or decision framework on this page.

Does this fit your situation? If you have confirmed that the Bridge and Part D are not workable and you want an FDA-approved cash-pay brand, see Ro’s current membership and medication pricing. If the real blocker is finding a clinician to evaluate and submit the Bridge PA, see Sesame’s current Medicare visit details.

For a broader non-Bridge comparison, use our Medicare GLP-1 Bridge alternatives guide. For a full self-pay decision path, see GLP-1 telehealth when Medicare does not cover the prescription.

A word on compounded GLP-1s

You will see compounded semaglutide and tirzepatide advertised at lower prices. We are not ranking them on this page, deliberately.

Compounded drugs are not FDA-approved. FDA does not review their safety, effectiveness, or quality before marketing. They are not Bridge-covered products and must never be described as interchangeable with Wegovy, Zepbound, or Foundayo. (FDA compounding Q&A)

For a reader who came here trying to preserve access to a federally administered path for FDA-approved products, collapsing compounded and approved medications into one table would blur the decision rather than help it.

What if I miss doses while this gets sorted out?

Answer capsule: Missed-dose and restart instructions differ by product, formulation, dose, and time since the last dose. Do not double a dose, restart at an old dose after a long interruption, or improvise a schedule from another GLP-1’s instructions; use the current FDA-approved Medication Guide and contact the pharmacist or prescriber who can see the actual prescription. Wegovy injection, Wegovy tablets, Foundayo, and Zepbound each have different missed-dose instructions. (Wegovy prescribing information; Zepbound prescribing information; Foundayo prescribing information)

Short section, on purpose.

Do not improvise. A pharmacy-access delay is an administrative problem, but the dosing response is a product-specific medical question.

Call the pharmacist and tell the prescriber if the gap is extending. They can use the current label, dose, and treatment history. This page cannot safely give one restart rule for Foundayo, Wegovy tablets, Wegovy injections, Wegovy HD, and Zepbound KwikPen because those are not one regimen.

Should I just wait for the permanent program?

Answer capsule: No permanent Part D weight-loss GLP-1 coverage is currently scheduled. On April 21, 2026, CMS delayed the Part D portion of BALANCE for calendar year 2027 pending further evaluation and data collection and extended the temporary Bridge through December 31, 2027. CMS describes future Part D implementation as potential—not guaranteed. (CMS BALANCE status update)

If you were planning to sit tight until something better arrives, do not build a medical-access plan around an unannounced future program.

Here is the timeline as it actually stands:

• December 23, 2025—CMS announced BALANCE and a temporary Bridge concept
• April 21, 2026—CMS announced that CY2027 Part D BALANCE implementation would be delayed pending further evaluation and data collection
• July 1, 2026—the Medicare GLP-1 Bridge launched
• December 31, 2027—the Bridge’s current scheduled end date (CMS BALANCE status update)

Do not call the April decision a May announcement or say CMS formally “delayed BALANCE indefinitely.” Some outside summaries use that phrase, but the official CMS notice says CY2027 implementation is delayed pending further evaluation and data collection to inform potential Part D implementation.

The basic Part D benefit continues to exclude agents when used for weight loss. CMS is using demonstration and model authority for the temporary Bridge and for any potential future BALANCE implementation; the current CMS notice does not schedule a permanent successor. (CMS Part D benefit manual; CMS BALANCE status update)

What this means for you: the $50 Bridge is available now for people who qualify and is scheduled through December 31, 2027. If your denial is correctable, the rational move is to fix the current claim rather than wait for a permanent program that has not been scheduled.

What should I do today after a Medicare GLP-1 Bridge denial?

Answer capsule: Work in this order: identify the decision-maker, obtain the full code and message, confirm Bridge routing, verify identity and product data, check initiation BMI and the correct coverage lane, then use the remedy that belongs to that exact problem. Do not file a Part D appeal unless the adverse decision came from the Part D process.

Stop when you reach the step that identifies your problem.

1. Find out what actually happened.
Pharmacy claim edit, Bridge PA decision, or Part D coverage determination?

2. Get the exact code and full message.
“Denied” is not enough information to act on.

3. Confirm the routing.
Bridge BIN 028918, PCN MEDDGLP1BR—not automatically the Part D billing route.

4. Check identity data.
Current MBI, first and last name, and DOB exactly as CMS has them.

5. Check the product and claim.
Current covered NDC, correct formulation, package quantity, strength, and one 28- or 30-day supply.

6. Check the PA.
Correct prescribing purpose, exact Part D-routing diagnoses, initiation BMI, cumulative threshold, all clinical answers, and complete prescriber fields.

7. Pick the right remedy.
Pharmacy correction, prescriber resubmission, Part D exception or appeal, Medicare/SSA record resolution, eligible replacement provider or pharmacy, or a separate cash-pay route.

Record this for your own follow-up

• Date and time
• Pharmacy name and location
• Exact code
• Full rejection message
• Drug, formulation, strength, and quantity
• Whether the claim used Bridge BIN/PCN
• Whether the prescriber received the PA request
• Who owns the next action
• Who you contacted
• Follow-up date

Do not put your Medicare number or Social Security number on a paper you will carry around, a public comment, or an ordinary email.

Micro-commitment: get the code today. You do not have to solve the whole case today. You need the one piece of information that tells you who can solve it.

How did we build and verify this guide?

Answer capsule: We compared nine official CMS and Medicare source sets, counted every row and distinct code in the June pharmacy tool, and converted 40 reason rows across 30 codes into nine action groups. Public comments were used only to identify recurring wording and workflow friction, never as authority for eligibility, medical, FDA, or coverage claims. (CMS reject-code tool; Medicare Rights Center public comments)

Who we are. Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. We are not a medical practice, insurance broker, government agency, Part D plan, pharmacy-benefit manager, central processor, or drug manufacturer.

How we made this. We read the current Bridge materials written for beneficiaries, prescribers, pharmacies, and Part D plans and compared their wording against the PA form and reject-code tool. We checked the cumulative BMI branches in Medicare.gov’s eligibility tool. We counted the technical rows and distinct codes and then assigned each to the person or organization that owns the next action.

We also reviewed the public comments visible on the Medicare Rights Center’s June 2026 article during our August 4 verification. We used those comments to identify confusion about mild OSA, initiation BMI, Part D routing, pharmacy refusal, and delayed handoffs. We did not use them to establish what CMS covers or whether anyone qualifies. (Medicare Rights Center public comments)

What we independently assembled:

• The nine-situation first-screen triage table
• The 40-row / 30-code / nine-action decoder
• The six current documentation seams
• The cumulative BMI decision table
• The source-of-denial responsibility framework
• The pharmacy script
• The prescriber resubmission checklist
• The provider-stated-versus-verified commercial fallback table

What we did not verify and will not pretend to know:

• Whether you personally qualify
• Whether a specific Part D plan must approve a specific prescription
• Whether a resubmission will succeed
• Pharmacy inventory
• A numerical Bridge approval or denial rate—CMS has not published one in the materials reviewed
• A universal limit on resubmissions—CMS does not publish a number and ties resubmission to corrected, updated, or additional information
• Whether Ro submits Bridge PAs
• Whether every Sesame clinician in every state can take every Bridge case

No medical review. This page has not been reviewed by a clinician, and we are not putting a doctor’s name on it to manufacture authority. It is a sourced guide to a federal program’s workflow. Medical decisions belong with the prescriber.

Refresh plan. Reverify monthly while the program is new:

• CMS page modification dates
• PA form and fax number
• BIN/PCN and help lines
• Products and NDCs
• Reject-code tool
• Clinical criteria and Part D routing
• 2027 Part D-utilization lookback
• BALANCE status
• Manufacturer cash prices
• Ro and Sesame pricing and program statements

Update the visible date only after the underlying sources have been checked.

Corrections. Publish a visible corrections contact and a dated change log. Do not silently overwrite a material rule.

Frequently asked questions

Answer capsule: These short answers cover the remaining questions about codes, appeals, supply limits, costs, plan types, eligibility, timing, and contact points. Each factual answer is tied to the current official source or the full explanation above.

Is reject code 75 a final denial?

No. Code 75 means prior authorization is required. It is the expected next response only after the claim clears earlier eligibility and claim edits. (CMS reject-code tool)

Can I appeal a Medicare GLP-1 Bridge denial?

No. CMS says there is no Bridge appeals process. The prescriber may resubmit if the original information was incorrect or if updated or additional information is available. (CMS provider guidance)

Is resubmission unlimited?

CMS does not publish a numeric retry limit, but it also does not promise unlimited unchanged resubmissions. Its published rule ties resubmission to corrected, updated, or additional information. (CMS provider guidance)

Does my Part D plan have to deny the drug first?

No. A Part D denial is not required. The required precursor is a denied claim submitted to the Bridge BIN and PCN before the Bridge PA is filed. (CMS provider guidance; official Bridge PA form)

Can I appeal a Part D denial?

Yes. The Bridge does not modify Part D coverage-determination, exception, or appeal rights. Follow the notice from the plan. (CMS Part D sponsor FAQ; Medicare.gov Part D appeal guide)

Does my current BMI or starting BMI count?

The form asks for BMI at the time GLP-1 therapy began. If treatment lowered it, the initial BMI should be selected. (official Bridge PA form)

Does prediabetes count at BMI 30–34.9?

Yes under the published cumulative thresholds. BMI 30–34.9 is also at least 27, and Medicare.gov’s eligibility tool presents all seven qualifying conditions for that branch. (CMS provider guidance; Medicare.gov Bridge coverage page)

Does mild sleep apnea automatically exclude me?

The current Bridge form asks about moderate-to-severe OSA. If a denial was based only on mild OSA, the prescriber should compare the denial reason with Question 2 and decide whether corrected information supports resubmission. (official Bridge PA form)

What does code 65 mean?

“Patient is not covered,” but the full message can describe six different situations: Part D enrollment, ineligible plan type, previous Part D GLP-1 use, deceased status, lawful-presence status, or incarceration status. Ask for the complete message. (CMS reject-code tool)

What does code 70 mean?

The submitted NDC is not currently eligible for the Bridge. The prescriber and pharmacy check whether a covered product or formulation is clinically appropriate. (CMS reject-code tool)

Does the Bridge cover Ozempic or Mounjaro?

No. The current Bridge list is Foundayo, Wegovy injection/tablets, and Zepbound KwikPen. Ozempic or Mounjaro may have a separate Part D route for a Part D-coverable indication. (CMS pharmacy guidance)

Does the Bridge cover Zepbound vials or single-dose pens?

No. Only the Zepbound KwikPen formulation is on the current Bridge list. (CMS pharmacy guidance)

Are pen needles covered?

No. CMS says Zepbound KwikPen needles are not covered by the Bridge and should not be billed to the Bridge or Part D. (CMS pharmacy guidance)

How long does a PA decision take?

CMS says the approval or denial is sent within 72 hours of PA submission. The pharmacy-to-prescriber request is typically transmitted within 24 to 72 hours before that. (CMS provider guidance)

How long is approval valid?

Through December 31, 2027 under the current rule, including refills and dose changes. Switching to a different covered GLP-1 requires a new PA. (CMS pharmacy guidance)

Can Extra Help lower the $50 Bridge copay?

No. The Bridge operates outside the Part D benefit, so the Part D low-income subsidy does not reduce the $50 Bridge copay. (CMS pharmacy guidance; CMS Part D sponsor FAQ)

Does the $50 count toward my Part D deductible or out-of-pocket limit?

No. It does not count toward the Part D deductible or TrOOP. Medicare.gov also says it will not appear on the Part D Explanation of Benefits or Medicare Summary Notice. (CMS pharmacy guidance; Medicare.gov Bridge coverage page)

Can I use the Medicare Prescription Payment Plan for the $50?

No. Bridge-dispensed GLP-1s are not eligible for that Part D payment program. (CMS Part D sponsor FAQ)

Can I use a manufacturer coupon on a Bridge claim?

No. CMS says coupons and discount programs may not be applied to Bridge claims. (CMS pharmacy guidance)

If I pay cash while waiting, can the Bridge reimburse me later?

No. The central processor does not accept paper claims or direct member reimbursement. (CMS pharmacy guidance)

Can I get a 90-day supply?

No. The Bridge permits a single 28- or 30-day supply per fill. (CMS pharmacy guidance)

Can I submit the PA myself?

No. The official form restricts submission to prescribing clinicians. (official Bridge PA form)

Does my pharmacy have to join the program?

No. Pharmacies do not opt in. They must be able to submit the claim correctly to the Bridge route. (CMS pharmacy guidance)

Does my Part D plan have to join?

No. Part D sponsors are not Bridge participants and do not opt in. The Bridge operates outside their coverage and payment flow. (CMS Part D sponsor FAQ)

I have TRICARE For Life. Am I eligible?

TRICARE For Life includes TRICARE pharmacy coverage and does not itself require Medicare Part D. Bridge access requires separate enrollment in an eligible Part D plan type and satisfaction of the other criteria. TRICARE says there is almost no advantage for most TFL beneficiaries to add Part D, so get case-specific TRICARE and SHIP guidance before changing coverage. (TRICARE Part D guidance; SHIP)

I am in PACE, a cost plan, or a private fee-for-service plan. Why not?

Those plan types are not Bridge-eligible unless the beneficiary is also enrolled in an applicable standalone PDP. (CMS pharmacy guidance)

I have both Medicare and Medicaid. Can I use the Bridge?

Dually eligible beneficiaries can use it when enrolled in an eligible Part D plan type and when they meet the PA criteria. The separate Bridge $50 copay does not receive the Part D low-income subsidy. (CMS pharmacy guidance)

Who checks my PA status?

The beneficiary can call 1-800-MEDICARE. The prescriber can call 855-273-0102. The pharmacy can call 844-673-0910 for claim questions and submitted-claim status. (CMS pharmacy guidance; Medicare.gov Bridge coverage page)

When does the Bridge end?

The current scheduled end date is December 31, 2027. CMS delayed CY2027 Part D BALANCE implementation pending further evaluation and data collection; it did not announce a guaranteed permanent successor. (CMS BALANCE status update)

What is the one thing I should do next?

Answer capsule: Get the exact reject code and full message from the pharmacy, then confirm whether the prescriber submitted the Bridge PA. Those two facts identify the responsible party and keep you from filing the wrong appeal or repeating an unchanged request.

If you take nothing else from this page, take this:

A rejection at the pharmacy counter is not automatically a verdict. Code 75 is a handoff. Another code is a troubleshooting instruction. A real Bridge denial has no appeal, but it may have a corrected-information resubmission path. A Part D denial is a different decision with different rights.

The single highest-value thing you can do in the next 24 hours is get the exact reject code and full message from the pharmacy and find out whether the prescriber actually submitted the Bridge PA.

Two calls. One code. One responsible party.

That is the whole first step.

Still not sure which GLP-1 program is right for you? Take our free 60-second matching quiz.

It is free, there is no email required to see your result, and it will route you toward the Bridge correction path, a Part D discussion, or a separate self-pay comparison based on the answers you provide. It is not a determination of Medicare eligibility.

Weight Loss Provider Guide is an independent comparison resource for GLP-1 telehealth providers. Some links on this page may be affiliate links, meaning we may earn a commission at no additional cost to you. Affiliate relationships do not influence our reporting of CMS rules, program requirements, code definitions, or routing guidance.

This page is educational and is not medical advice, legal advice, insurance advice, or a determination of Medicare eligibility. Program rules, prices, products, NDCs, and commercial policies change. Confirm current information with CMS, Medicare.gov, your Part D plan, pharmacy, and prescriber.

Last verified: August 4, 2026 · Version 1.0

Primary-source record

• CMS Medicare GLP-1 Bridge overview for beneficiaries
• CMS Medicare GLP-1 Bridge: Information for Providers
• CMS Medicare GLP-1 Bridge: Information for Pharmacies
• CMS Medicare GLP-1 Bridge: Information for Part D Plans
• Medicare.gov: Weight-loss drug coverage and Bridge eligibility tool
• Official Medicare GLP-1 Bridge Prior Authorization Request Form
• CMS Medicare GLP-1 Bridge Prescriber Fact Sheet
• CMS Pharmacy NCPDP Reject Code Troubleshooting Reference Tool
• CMS Medicare GLP-1 Bridge Expectations and FAQs for Part D Sponsors
• CMS Status Update on the Bridge and BALANCE in Part D for CY2027
• Medicare.gov Part D appeal guidance
• FDA compounding questions and answers
• Official Wegovy self-pay terms
• Official Foundayo self-pay terms
• Official Zepbound self-pay terms
• Ro official pricing and Sesame’s Medicare-focused program page, used only for the clearly labeled commercial routes